Synthesis of ximelagatran, melagatran, hydroxymelagatran, and ethylmelagatran in H-3 labeled form.

In support of a study designed to better understand the liver toxicity of ximelagatran, ximelagatran, and melagatran, hydroxymelagatran and ethylmelagatran were prepared in tritium labeled form. Incorporation of tritium was achieved by hydrogen isotope exchange using Crabtree's catalyst and later with N-heterocyclic containing Ir catalyst. The tritiated product was then converted into the four target compounds to afford them in high purity and specific activity.

Erucamide as a modulator of water balance: new function of a fatty acid amide.

The aim of this study was to isolate a compound from blood plasma that inhibits intestinal diarrhea and that appears also to regulate fluid volumes in other organs. The isolation procedure included lipid extraction, liquid chromatography, and gas chromatography. The active substance was identified by mass spectrometry as erucamide (MW 337 Da). The biological effect was reproduced with authentic erucamide. Erucamide is a fatty acid amide, such as oleamide and anandamide, which modulate other physiological functions in a receptor-mediated fashion. All the exact biological functions of erucamide are as yet to be defined, but it is already known to stimulate angiogenesis. Erucamide concentrations were determined in body organs from the pig. The blood plasma level was 3 ng/g, and those of lung, kidney, liver, and brain were 12, 2.5, 1.0, and 0.5 ng/g, respectively. Erucamide was below detection level in the intestine, but is known to be present in the cerebrospinal fluid. In the rat, 3H-erucamide was accumulated in vivo into lung, liver, and spleen and in vitro into lung, liver, brain, and intestine. The in vitro uptake was time and temperature dependent, but not saturable.

Synthesis, Structure, and Photophysical Properties of Novel Ruthenium(II) Carboxypyridine Type Complexes.

A series of Ru(II) compounds and salts have been synthesized: [Ru(6-carboxylato-bpy)(2)] (5), [Ru(6-carboxylato-bpy)(tpy)]PF(6) (9), [Ru(tpy)(2)](PF(6))(2) (8), and [Ru(bpy)(2)(Pic)]PF(6) (11), where 6-carboxy-bpy (1) = 6-carboxy-2,2'-bipyridine, tpy (2) = 2,2':6',2"-terpyridine, and Pic = 2-carboxylatopyridine. The compounds have been characterized by NMR, electrospray mass spectrometry (ESI-MS), cyclic voltammetry, absorption and emission spectroscopy (at 100, 140, and 298 K), and single-crystal X-ray diffraction (complex 5). Complex 5 crystallizes in the monoclinic system, space group P2(1)/n, formula RuC(22)H(14)N(4)O(4).C(2)H(5)OH, with a = 11.088(3) Å, b = 11.226(3) Å, c = 35.283(9) Å, beta = 91.41(2) degrees, and Z = 8. A linear dependence on the number of coordinated carboxylato groups and the electrochemical redox potentials was found, ca. 0.4 V lower reduction potential for the oxidation step (Ru(II/III)) per carboxylate group. Also, to the best of our knowledge, these are the first examples (9, 11) of mononuclear Ru(II) complexes containing a carboxypyridine-ruthenium moiety displaying any luminescence emission.